Bath & Body Works (NYSE:BBWI – Get Free Report) issued an update on its third quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.41-0.47 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of flat to +2.5% yr/yr to ~$1.56-1.60 billion, compared to the consensus revenue estimate of $1.58 billion. Bath & Body Works also updated its FY25 guidance to $3.06-3.26 EPS.
Bath & Body Works Price Performance
NYSE:BBWI opened at $32.39 on Friday. Bath & Body Works has a 1-year low of $26.20 and a 1-year high of $52.99. The company has a 50-day moving average of $31.85 and a 200 day moving average of $40.31. The firm has a market cap of $7.10 billion, a PE ratio of 8.35, a price-to-earnings-growth ratio of 0.96 and a beta of 1.77.
Bath & Body Works (NYSE:BBWI – Get Free Report) last announced its quarterly earnings results on Wednesday, August 28th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.02. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Bath & Body Works had a net margin of 12.69% and a negative return on equity of 41.94%. Sell-side analysts anticipate that Bath & Body Works will post 3.18 EPS for the current fiscal year.
Bath & Body Works Dividend Announcement
Analyst Upgrades and Downgrades
Several brokerages have recently commented on BBWI. Deutsche Bank Aktiengesellschaft decreased their price objective on Bath & Body Works from $57.00 to $54.00 and set a buy rating for the company in a report on Monday, August 26th. Morgan Stanley cut their price objective on shares of Bath & Body Works from $56.00 to $51.00 and set an overweight rating on the stock in a report on Thursday, September 5th. UBS Group lowered their target price on shares of Bath & Body Works from $52.00 to $38.00 and set a neutral rating for the company in a research note on Thursday, August 29th. BMO Capital Markets restated an outperform rating and set a $50.00 price target (down previously from $52.00) on shares of Bath & Body Works in a research note on Thursday, August 29th. Finally, Wells Fargo & Company decreased their price target on shares of Bath & Body Works from $48.00 to $40.00 and set an equal weight rating for the company in a report on Wednesday, July 24th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $42.35.
View Our Latest Stock Analysis on Bath & Body Works
Bath & Body Works Company Profile
Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.
See Also
- Five stocks we like better than Bath & Body Works
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- MarketBeat Week in Review – 9/23 – 9/27
- What Makes a Stock a Good Dividend Stock?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.